Concert Pharma (CNCE) Tops Q3 EPS by 12c

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.51), $0.12 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $26 thousand versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M